Syncona Limited (SYNC.L), a British life science investment trust, on Thursday reported a narrower net loss for the full year, mainly due to lesser investment losses.
For the 12-month period to March 31, the company posted a pre-tax loss of GBP 8.805 million, compared with a pre-tax loss of GBP 143.160 million last year. Net loss stood at GBP 8.805 million, or 1.45 pence per share, as against the prior year's net loss of GBP 143.160 million, or 22.48 pence per share.
Net losses on financial assets at fair value through profit or loss were GBP 29.061 million, compared with losses of GBP 187.979 million a year ago. Total investment income slipped to GBP 49.334 million from GBP 66.539 million in the previous year.
Syncona reported total net assets of GBP 1.037 billion, less than the GBP 1.053 billion last year. Net asset value per share stood at GBP 1.71 per share, compared with GBP 1.71 per share a year ago.
Looking ahead, the company said: "We believe that continued pharma M&A activity and improvement in market conditions, should be supportive to the delivery of Syncona's new investment policy and our initial focus on returning a minimum of £250 million to shareholders in a timely manner. The Board is also pleased that Syncona Investment Management Limited has continued to make progress in raising a private fund, independent of the company, which will focus on the significant opportunity to leverage the UK's significant research base to create, build and scale globally competitive life science companies".
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.